---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-24-000027"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:09:45.243124+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track

## Summary
- Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.
- Net loss $4.9M ($1.17/share) vs $4.5M ($2.16/share) in Q1 2023; revenue $1.0M from milestone.
- R&D spend $2.6M, down from $3.9M YoY; G&A $4.0M, up from $3.5M.
- First Phase 3 cadisegliatin trial in T1D expects first patient enrollment Q2 2024, top-line data Q1 2026.
- Planning two international registrational trials for cadisegliatin in T1D starting 2026; T2D Phase 2 in Middle East on track H2 2024.

## SEC filing metadata
- accession: 0001641489-24-000027
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/0001641489-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/vtvt-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-24-000027
- JSON: https://secwatch.observer/filing/0001641489-24-000027.json
- Plain text: https://secwatch.observer/filing/0001641489-24-000027.txt

## Key facts
- Earnings Releases
  vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/0001641489-24-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.